本頁面由Tiger Trade Technology Pte. Ltd.提供服務

STARPHARMA HOLDINGS LTD

0.705
-0.080-10.19%
成交量:396.91萬
成交額:291.61萬
市值:3.36億
市盈率:-41.47
高:0.780
開:0.780
低:0.705
收:0.785
52周最高:0.830
52周最低:0.117
股本:4.77億
流通股本:3.48億
量比:1.80
換手率:1.14%
股息:- -
股息率:- -
每股收益(TTM):-0.017
每股收益(LYR):-0.020
淨資產收益率:-45.55%
總資產收益率:-21.00%
市淨率:24.41
市盈率(LYR):-35.25

資料載入中...

公司資料

公司名字:
STARPHARMA HOLDINGS LTD
交易所:
ASX
成立時間:
1997
員工人數:
50
公司地址:
4-6 Southampton Crescent,Abbotsford,Victoria,Australia
郵編:
3067
傳真:
61 3 9510 5955
簡介:
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1/2 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.